The BRILLIANT 011, a first-in-human clinical trial, was officially launched at the Desmond Tutu HIV Foundation (DTHF) ...
South Africa has begun the first human trials of a locally developed HIV vaccine to defeat a virus that still kills around one person per minute worldwide.
Hosted on MSN
Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies
A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional ...
The BRILLIANT 011 trial is testing two next-generation HIV vaccine components—BG505 GT1.1 and 426c.Mod.Core-C4b—administered ...
One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...
For nearly 15 years, Dennis Burton worked on a project aimed at solving what he calls "one of the most difficult problems in biomedicine" — creating an HIV vaccine. That work was funded by the largest ...
The current presidential administration has ended funding for the Center for HIV/AIDS Vaccine Development (CHAVD), a move that researchers say will likely set efforts to end HIV globally back by a ...
On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine development program will end... For nearly 15 years, Dennis Burton worked on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results